Your browser is no longer supported. Please, upgrade your browser.
BLU BELLUS Health Inc. monthly Stock Chart
BELLUS Health Inc.
Index- P/E- EPS (ttm)-0.60 Insider Own3.30% Shs Outstand60.45M Perf Week-4.22%
Market Cap227.45M Forward P/E- EPS next Y-0.60 Insider Trans0.00% Shs Float50.74M Perf Month18.00%
Income-34.20M PEG- EPS next Q-0.12 Inst Own42.35% Short Float1.61% Perf Quarter20.41%
Sales0.02M P/S13170.71 EPS this Y-168.90% Inst Trans-0.04% Short Ratio0.58 Perf Half Y-71.88%
Book/sh1.92 P/B1.54 EPS next Y- ROA-31.30% Target Price- Perf Year-57.25%
Cash/sh0.91 P/C3.24 EPS next 5Y- ROE-33.20% 52W Range2.01 - 12.03 Perf YTD-61.18%
Dividend- P/FCF- EPS past 5Y-37.70% ROI- 52W High-75.48% Beta0.41
Dividend %- Quick Ratio11.60 Sales past 5Y- Gross Margin- 52W Low46.77% ATR0.19
Employees17 Current Ratio11.60 Sales Q/Q-57.10% Oper. Margin- RSI (14)64.67 Volatility8.57% 6.95%
OptionableNo Debt/Eq0.01 EPS Q/Q48.90% Profit Margin- Rel Volume0.79 Prev Close2.95
ShortableYes LT Debt/Eq0.00 EarningsNov 12 Payout- Avg Volume1.41M Price2.95
Recom- SMA2014.79% SMA5021.16% SMA200-51.91% Volume1,117,183 Change0.00%
Nov-18-20Initiated Evercore ISI Outperform $12
Jul-07-20Downgrade Guggenheim Buy → Neutral
Jun-26-20Initiated H.C. Wainwright Buy $28
Sep-30-19Initiated Jefferies Buy $20
Sep-30-19Initiated Guggenheim Buy $12
Sep-30-19Initiated Cowen Outperform
Nov-24-20 07:00AM  
Nov-12-20 07:00AM  
Nov-10-20 07:00AM  
Nov-05-20 12:30PM  
Oct-23-20 07:04AM  
Oct-22-20 09:20AM  
Oct-19-20 11:25PM  
Sep-08-20 07:00AM  
Sep-07-20 08:19AM  
Sep-03-20 07:00AM  
Aug-31-20 05:00PM  
Aug-13-20 03:55PM  
Aug-06-20 12:30PM  
Jul-31-20 01:39PM  
Jul-19-20 07:30PM  
Jul-13-20 01:40PM  
Jul-10-20 12:45PM  
Jul-09-20 09:40PM  
Jul-08-20 03:18PM  
Jul-07-20 05:41AM  
Jul-06-20 03:26PM  
Jun-27-20 09:28PM  
Jun-19-20 05:24PM  
Jun-18-20 08:14AM  
May-28-20 07:00AM  
May-22-20 07:25AM  
May-14-20 06:55PM  
May-13-20 07:59AM  
May-06-20 07:00AM  
May-05-20 05:00PM  
Apr-07-20 12:02PM  
Apr-06-20 05:00PM  
Mar-25-20 02:07PM  
Mar-23-20 07:31AM  
Mar-19-20 07:00AM  
Feb-27-20 05:00PM  
Feb-21-20 05:18AM  
Feb-20-20 07:00AM  
Jan-16-20 05:21AM  
Dec-13-19 11:16AM  
Dec-06-19 12:03PM  
Dec-02-19 10:11AM  
Oct-19-19 08:50AM  
Sep-19-19 01:02PM  
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.